Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 400

1.

Transcranial direct current stimulation (tDCS) for idiopathic Parkinson's disease.

Elsner B, Kugler J, Pohl M, Mehrholz J.

Cochrane Database Syst Rev. 2016 Jul 18;7:CD010916. doi: 10.1002/14651858.CD010916.pub2. Review.

PMID:
27425786
2.

Levodopa therapy for Parkinson disease: A look backward and forward.

LeWitt PA, Fahn S.

Neurology. 2016 Apr 5;86(14 Suppl 1):S3-12. doi: 10.1212/WNL.0000000000002509. Epub 2016 Apr 4. Review.

PMID:
27044648
3.

Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety.

Dhall R, Kreitzman DL.

Neurology. 2016 Apr 5;86(14 Suppl 1):S13-24. doi: 10.1212/WNL.0000000000002510. Epub 2016 Apr 4. Review.

PMID:
27044646
4.

Restless legs syndrome associated with major diseases: A systematic review and new concept.

Trenkwalder C, Allen R, Högl B, Paulus W, Winkelmann J.

Neurology. 2016 Apr 5;86(14):1336-43. doi: 10.1212/WNL.0000000000002542. Epub 2016 Mar 4. Review.

PMID:
26944272
5.

Induced pluripotent stem cells and Parkinson's disease: modelling and treatment.

Xu X, Huang J, Li J, Liu L, Han C, Shen Y, Zhang G, Jiang H, Lin Z, Xiong N, Wang T.

Cell Prolif. 2016 Feb;49(1):14-26. doi: 10.1111/cpr.12229. Epub 2016 Jan 8. Review.

PMID:
26748765
6.

Feasibility, appropriateness, meaningfulness and effectiveness of nursing interventions on the well-being of people with Parkinson's disease and their caregivers living in the community: a mixed-methods systematic review protocol.

Wosinski J, Delmas P, Bouwers B, Stormacq C, Kiszio B.

JBI Database System Rev Implement Rep. 2015 May 15;13(4):14-29. doi: 10.11124/jbisrir-2015-1864. Review. No abstract available.

PMID:
26447070
8.

Insights from late-onset familial parkinsonism on the pathogenesis of idiopathic Parkinson's disease.

Volta M, Milnerwood AJ, Farrer MJ.

Lancet Neurol. 2015 Oct;14(10):1054-64. doi: 10.1016/S1474-4422(15)00186-6. Review.

PMID:
26376970
9.

Rasagiline for the treatment of Parkinson's disease: an update.

Stocchi F, Fossati C, Torti M.

Expert Opin Pharmacother. 2015;16(14):2231-41. doi: 10.1517/14656566.2015.1086748. Review.

PMID:
26364897
10.

Treadmill training for patients with Parkinson's disease.

Mehrholz J, Kugler J, Storch A, Pohl M, Hirsch K, Elsner B.

Cochrane Database Syst Rev. 2015 Sep 13;(9):CD007830. doi: 10.1002/14651858.CD007830.pub4. Review.

PMID:
26363646
11.

Electroconvulsive therapy in Parkinson's disease.

Calderón-Fajardo H, Cervantes-Arriaga A, Llorens-Arenas R, Ramírez-Bermudez J, Ruiz-Chow Á, Rodríguez-Violante M.

Arq Neuropsiquiatr. 2015 Oct;73(10):856-60. doi: 10.1590/0004-282X20150131. Epub 2015 Sep 1. Review.

12.

Treadmill training for patients with Parkinson's disease.

Mehrholz J, Kugler J, Storch A, Pohl M, Elsner B, Hirsch K.

Cochrane Database Syst Rev. 2015 Aug 22;(8):CD007830. doi: 10.1002/14651858.CD007830.pub3. Review. Update in: Cochrane Database Syst Rev. 2015;(9):CD007830.

PMID:
26297797
13.

Specific Brain Lesions Impair Explicit Motor Imagery Ability: A Systematic Review of the Evidence.

McInnes K, Friesen C, Boe S.

Arch Phys Med Rehabil. 2016 Mar;97(3):478-489.e1. doi: 10.1016/j.apmr.2015.07.012. Epub 2015 Aug 5. Review.

PMID:
26254950
14.

The retromer complex in development and disease.

Wang S, Bellen HJ.

Development. 2015 Jul 15;142(14):2392-6. doi: 10.1242/dev.123737. Review.

15.

Chemical biology of compounds obtained from screening using disease models.

Tashiro E, Imoto M.

Arch Pharm Res. 2015 Sep;38(9):1651-60. doi: 10.1007/s12272-015-0633-4. Epub 2015 Jul 17. Review.

PMID:
26177809
16.

[Subtypes of mild cognitive impairment in Parkinson's disease and factors predicting its becoming dementia].

Toribio-Diaz ME, Carod-Artal FJ.

Rev Neurol. 2015 Jul 1;61(1):14-24. Review. Spanish.

17.

The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration.

Deger JM, Gerson JE, Kayed R.

Aging Cell. 2015 Oct;14(5):715-24. doi: 10.1111/acel.12359. Epub 2015 Jun 5. Review.

18.

Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations.

Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, Singleton A, Olanow CW, Merchant KM, Bezard E, Petsko GA, Meissner WG.

Lancet Neurol. 2015 Aug;14(8):855-66. doi: 10.1016/S1474-4422(15)00006-X. Epub 2015 Jun 3. Review.

PMID:
26050140
19.

Gastrointestinal dysfunction in Parkinson's disease.

Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF.

Lancet Neurol. 2015 Jun;14(6):625-39. doi: 10.1016/S1474-4422(15)00007-1. Review.

PMID:
25987282
20.

G-quadruplexes: Emerging roles in neurodegenerative diseases and the non-coding transcriptome.

Simone R, Fratta P, Neidle S, Parkinson GN, Isaacs AM.

FEBS Lett. 2015 Jun 22;589(14):1653-68. doi: 10.1016/j.febslet.2015.05.003. Epub 2015 May 13. Review.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk